Multiple sclerosis – www.brainwork.md

25th September 2019

Why B-cell therapies, or why not?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-bcelltherapy.jpg 3848 2300 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 25th September 2019 4th October 2019

The rational for B-cell therapy in multiple sclerosis (MS) was presented during ECTRIMS 2019, with David Baker (Blizard Institute, Queen Mary University of London, UK) posing the question of why…

Peter Stevenson, PhD
0
0

24th September 2019

Are stem cells in MS ready for prime time?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-stem-cells.jpg 2300 1535 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 24th September 2019 26th September 2019

Hot topics continued at ECTRIMS 2019 in Stockholm with Joachim Burman (Department of Neurology, Uppsala University Hospital, Sweden), who stepped up to the podium to discuss autologous haematopoietic stem cell transplantation (aHSCT)…

Peter Stevenson, PhD
0
0

24th September 2019

Enough evidence for vitamin D in MS?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-vitamin-D.jpg 3450 2300 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 24th September 2019 26th September 2019

The role of vitamin D in the treatment of multiple sclerosis (MS) took centre stage during the first day of ECTRIMS 2019 in Stockholm, Sweden. In a ‘Hot Topic’ session,…

Peter Stevenson, PhD
0
0

ECTRIMS 2019

https://www.brainwork.md/content/uploads/2019/07/Brainwork-Stockholm.jpg 2300 3450 Rachel Park, MA Rachel Park, MA https://secure.gravatar.com/avatar/4ebf9310e1faab0e0e0630445cf726cb?s=96&d=mm&r=g 30th July 2019 24th September 2019

https://www.brainwork.md/tag/ectrims/

9th July 2019

Natalizumab treatment associated with reduction of gliotic biomarkers in white matter

https://www.brainwork.md/content/uploads/2019/07/Brainwork-Natalizumab.jpg 3067 2300 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 9th July 2019 9th July 2019

New data on the effect of natalizumab treatment on neuronal and membrane integrity in lesional white matter were presented at the recent 5th Annual Congress of the European Academy of…

Michael Furrer, PhD
0
0

9th July 2019

Serum NfL levels shine a light on neuroaxonal damage and disease

https://www.brainwork.md/content/uploads/2019/07/Brainwork-NfL.jpg 4089 2300 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 9th July 2019 9th July 2019

The 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, featured an in-depth exploration of the role of neurofilament light chain (NfL) protein levels as a…

Michael Furrer, PhD
0
0

9th July 2019

Cellular power failures linked to Parkinsonism

https://www.brainwork.md/content/uploads/2019/07/Brainwork-Parkinsonism.jpg 3150 2100 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 9th July 2019 9th July 2019

Mounting evidence is linking neurodegenerative disorders, such as Parkinsonism and dementia, with mitochondrial dysfunction.1 At the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, the…

Mea Holm, PhD
0
0

4th July 2019

8-year follow-up data of alemtuzumab presented

https://www.brainwork.md/content/uploads/2019/07/follow-up-data-of-alemtuzumab-presented-image.jpg 1920 1280 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 4th July 2019 9th July 2019

An update of the long-term efficacy and safety data of alemtuzumab in patients with relapsing-remitting MS was presented at the 5th Annual Congress of the European Academy of Neurology (EAN)…

Michael Furrer, PhD
0
0

17th May 2019

Establishing sNfL as an MS Biomarker

https://www.brainwork.md/content/uploads/2019/05/Brainwork-MSBiomarkers.jpg 3300 2200 Carlotta Foletti, PhD Carlotta Foletti, PhD https://secure.gravatar.com/avatar/c8bf2814aa3641344dd6e3b11325ad20?s=96&d=mm&r=g 17th May 2019 17th May 2019

At the ECTRIMS annual congress in October 2018, there was a lot of talk on serum neurofilament light (sNfL) becoming the first blood biomarker predicting neuronal damage caused by neurological…

Carlotta Foletti, PhD
0
0

17th May 2019

News from the ocrelizumab front

https://www.brainwork.md/content/uploads/2019/05/Brainwork-NewsOcrelizumab.jpg 3300 2200 Carlotta Foletti, PhD Carlotta Foletti, PhD https://secure.gravatar.com/avatar/c8bf2814aa3641344dd6e3b11325ad20?s=96&d=mm&r=g 17th May 2019 17th May 2019

In our ongoing coverage of the AAN Annual Meeting in Philadelphia, we are focusing on select posters reporting on studies of ocrelizumab, an intravenous humanised monoclonal antibody that selectively targets…

Carlotta Foletti, PhD
0
0